Natural killer (NK) cells play a key role in defense against tumor cells that have the capacity to downregulate human leukocyte antigen (HLA) class I expression. It has been reported that leukemic cells can have downregulated expression of HLA class I molecules. The polymorphic nature of NK cell receptor (NKR) genes generates diverse repertoires in the human population, which display specificity in the innate immune response. In the present study, 11 KIR and two CD94/NKG2 receptors were genotyped by PCR-SSP in 96 leukemic patients and 148 healthy Caucasians. Here, we report a significant increased frequency of the more inhibitory AB killer cell immunoglobulin-like receptor (KIR) phenotype in leukemic patients compared to the controls (31.1% in healthy controls vs 51.0% in leukemic patients, P c ¼ 0.002), which is related to the high prevalence of the inhibitory KIR2DL2 in this population (P c ¼ 0.007). Moreover, two specific KIR phenotypes AB1 and AB9, including all inhibitory KIRs, were significantly associated with leukemic patients. Our study suggests that an important percentage of leukemic patients express a KIR phenotype in favor of escape from NK cell immunity.
Introduction
The capacity of natural killer (NK) cells to lyse tumor cells spontaneously and their potent antileukemic cytotoxic activity in vitro suggest important functions for this cell type in the in vivo antileukemia immune response. [1] [2] [3] The functional activity of NK cells is regulated by distinct cell surface receptors integrating a balance between positive and negative signals that either trigger or block NK cell cytotoxicity. It has been shown that disruption of a dominant-negative signal by reduced expression of human leukocyte antigen (HLA) class I molecules on target cells, might trigger NK cell cytotoxicity mediated by the activating receptors. 4 Human NK cells express two types of receptors, the killer cell immunoglobulin-like receptors (KIRs) and the CD94/NKG2 lectin-like receptors, which can signal inhibition or activation when HLA class I molecules are detected. 5, 6 Prominent among these HLA class I-specific receptors are the KIRs, which are encoded by a diverse and rapidly evolving family of 15 polymorphic genes located on chromosome 19 . 7 The KIR family has been subdivided according to the number of external immunoglobulin (Ig) domains (2D or 3D) and whether they have a long (L) or short (S) cytoplasmic tail that corresponds to their function as inhibitory or activating receptors, respectively (www.ncbi.nlm.nih.gov/PROW). KIRs with two Ig domains (KIR2DL1, KIR2DL2, KIR2DL3) have been shown to interact with specific HLA-C alleles 8, 9 and those including three Ig domains (KIR3DL1 and KIR3DL2) to bind with HLA-Bw4 10 and HLA-A3/A11, 11 respectively. Within the human population, the variation of KIR haplotypes mostly depends on the number and type of KIR genes that they inherit. Based on the gene content, two major KIR haplotype groups, A and B, have been defined in the human population. The group A haplotypes, which is the most common Caucasian haplotype, is characterized by the presence of inhibitory receptors KIR2DL1 and KIR2DL3, with the B haplotype instead containing only KIR2DL2. 12, 13 Furthermore, the B haplotypes are more diverse and contain more activating receptors compared to the A haplotypes that contain only one activating receptor (KIR2DS4).
The second receptor family, including a heterodimer of CD94 and a member of the NKG2 receptor family, is encoded by conserved genes located on chromosome 12.
14, 15 The CD94/ NKG2 heterodimers has been shown to recognize the nonclassical HLA-E molecule and depending on the type of NKG2 receptor the generated signal can be inhibiting (NKG2A) or activating (NKG2C and NKG2E). 16 Recently, our 17 and other studies [18] [19] [20] demonstrated that leukemic cells can have downregulated expression of HLA class I molecule and putative allele loss. [17] [18] [19] [20] Moreover, recent studies support a major role for NK cells in the graft-versusleukemia effect in allogeneic stem cell transplantation. [21] [22] [23] These data demonstrate that NK cells could play an important role in the innate immune surveillance of leukemic cells. As a result of the variable KIR gene content in individual genomes that regulate the function of NK cells, the innate immune response to control diseases, including leukemia, may vary among humans.
The aim of the present study is to investigate whether leukemic patients could have disease-specific NK cell receptor (NKR) phenotypes that might not be able to detect malignant cells with altered HLA class I expression.
Patients and methods

Patients and controls
The patient group consisted of 96 unrelated Belgian Caucasians with chronic myeloid leukemia (CML) (n ¼ 20), acute myeloid leukemia (AML) (n ¼ 29), chronic lymphoid leukemia (CLL) (n ¼ 39) and acute lymphoid leukemia (ALL) (n ¼ 8). The control population consisted of 148 unrelated, apparently healthy, randomly selected Belgian Caucasians. From each patient, a blood sample was collected at the Department of Hematology of the Institut Jules Bordet or the Academisch Ziekenhuis-VUB, Brussels, Belgium. The blood samples from healthy controls were obtained at the Blood Transfusion Center of the Academisch Ziekenhuis-VUB, Brussels, Belgium.
NK cell receptor genotyping
Genomic DNA was extracted from peripheral blood using a QIAamp DNA mini kit (Qiagen, Leusden, The Netherlands) and genotyped for presence or absence of five groups of inhibitory KIR (2DL1, 2DL2, 2DL3, 3DL1 and 3DL2), six groups of activating KIR (2DS1, 2DS2, 2DS3, 2DS4, 2DS5 and 3DS1) and two CD94/NKG2 genes (NKG2A and NKG2C).
Genotyping was performed using PCR amplification with primers specific for each locus (PCR-SSP). The PCR-SSP assays were based essentially on the primers and conditions described by Uhrberg et al, 12 with little modifications. 24, 25 We amplified 100-200 ng DNA in a 25 ml PCR mixture containing 2.5 ml 10 Â PCR buffer, 3-4 mM MgCl 2 , 0.2 mM dNTPs, 5 pm of each specific primer and 0.750 UI Taq DNA polymerase (Invitrogen, Merelbeke, Belgium). All amplifications were performed in a 9600 thermal cycler (PE9600, Applied Biosystems, Belgium). Depending on the optimized amplification temperature and conditions, three distinct thermocycler programs were used. KIR2DL1-3, KIR3DL2, KIR2DS2-3, KIR3DS1, NKG2A and NKG2C were amplified under the same conditions described by Uhrberg. 12 Amplifications of KIR3DL1, KIR2DS1 and KIR2DS4, were carried out using the same conditions except that the annealing temperature was decreased by 21C. 24 A special PCR profile was performed for the amplification of KIR2DS5: initial denaturation at 951C for 5 min; five cycles of 971C for 20 s, 621C for 45 s, and 721C for 90 s; followed by 30 cycles of 951C for 20 s, 641C for 45 s, and 721C for 90 s; and a 10 min extension at 721C. We used platinum Taq DNA polymerase (Invitrogen, Life Technologies, Merelbeke, Belgium) instead of normal Taq DNA polymerase (Invitrogen) for the amplification of KIR3DL1, KIR2DS1, KIR2DS4 and KIR2DS5. Modification of the PCR conditions and the use of platinum Taq DNA polymerase improved the specificity of the PCR results.
Each PCR experiment included one negative and positive control. DNA from cell lines positive or negative for that particular NKR gene, were kindly provided by Dr V Lepage (Hô pital St Louis, Paris, France). Every DNA sample was first controlled for presence of the framework KIR3DL2 gene before other NKR genes were typed.
The amplified products were analyzed in a 2% agarose gel, prestained with ethidium bromide.
Statistical analysis
Phenotype frequencies were determined by direct counting. Genotype frequencies were calculated using the formula: 1À(1Àphenotype frequency) 1/2 . Differences between leukemic patients and controls in the distribution of NKR genes and KIR phenotypes were estimated by w 2 -test, and Yates-corrected P-values (P c ) were subjected to correction for the number of NKR genes analyzed. 26, 27 The absolute linkage disequilibrium (D) parameters for pairs of KIR genes were determined using the method of Mattiuz et al. 28 The significance of D between the presence of two KIR genes was tested by the w 2 -test (Yates correction).
Results
NKR frequencies
Univariate comparison of individual NKR (KIR and CD94/ NKG2) frequencies between healthy controls (n ¼ 148) and leukemic patients (n ¼ 96) was conducted ( Table 1 ).
The inhibitory KIR3DL2 and NKG2A were present in 100% of the leukemic patients and healthy controls, in agreement with most previous published population studies. 12, 13, 24, 26, 27, 29, 30 The inhibitory KIR3DL1 for HLA-Bw4 was positive in all patient samples except for one patient with CML. We observed a significantly higher frequency (P c ¼ 0.007) of the inhibitory KIR2DL2 in the total leukemic patient group compared to the controls. Therefore, the occurrence of having two inhibitory KIRs (2DL2/2DL3 heterozygous) for group 1 HLA-C antigens was much higher in these patients (33% in healthy controls vs 52% in leukemic patients) (data not shown). Owing to a strong positive linkage between KIR2DL2 and KIR2DS2, we observed a higher frequency of the activating KIR2DS2 in the leukemic patients group (P c ¼ 0.022).
Finally, we found four patients (one patient with AML, one patient with CLL and two patients with ALL) who were negative for the activating NKG2C gene in contrast to only one individual in the control group.
Major KIR phenotype analysis
can be identified dependent on the presence or absence of members of the inhibitory KIR2DL family. Individuals having phenotypes, which could not be accounted by the proposed model of Uhrberg et al 12 and Witt et al 13 were grouped as others. The AA, BB, AB and other KIR phenotypes were counted in our leukemic population and compared to those obtained in the healthy controls (Figure 1 ). The frequency of the putative AA homozygotes was significantly higher in the control population than in the leukemic patient population (56.9% in healthy controls vs 38.5% in leukemic patients, P c ¼ 0.011). In contrast, the frequency of the putative AB heterozygotes was significantly higher in the leukemic patient group (31.1% in healthy controls vs 51.0% in leukemic patients, P c ¼ 0.002). The frequency of BB homozygotes was the same in both populations (8.8% in healthy controls vs 8.3% in leukemic patients, P c ¼ 0.912).
Specific KIR phenotype analysis
These major KIR phenotypes can be further classified in more specific KIR phenotypes based on the presence or absence of other investigated KIRs. The nomenclature method from Uhrberg et al 12 and Witt et al 13 and developed further by Norman et al 26 is used to describe these specific KIR phenotypes. The distribution of the different KIR phenotypes observed in the two populations is shown in Table 2 .
In the control group (n ¼ 148), 45 different KIR phenotypes were observed and 10 out of 45 have not been reported earlier, whereas the patient group (n ¼ 96) consisted of 30 distinct KIR phenotypes of which five have not been previously identified (data not shown).
A more diverse range of AA phenotypes was observed in the controls than in the leukemic patients. The most frequent KIR phenotype expressed in the healthy controls was AA1 (31.1%), consistent with all other Caucasoid populations. 13, 24, 26, 27, 29 Phenotype AA1 is composed of seven KIR loci (2DL1, 2DL3, 2DL4, 3DL1, 3DL2, 3DL3 and 2DS4). 13, 26 In contrast, in the leukemic patients, the prevailing KIR phenotype was AB1 (2DL1, 2DL2, 2DL3, 2DL4, 3DL1, 3DL2, 3DL3, 2DS2 and 2DS4) with 20.8% frequency, which is higher compared to the other Caucasoid populations studied 13, 24, 26, 27 and is Natural killer cell receptor phenotypes in leukemia S Verheyden et al significantly increased (31%) in patients with AML (P c ¼ 0.017). Another KIR phenotype AB9 was detected in nine of the 96 patients (9.4%) and was significantly associated with CML patients (P c ¼ 0.020). This KIR phenotype has one activating KIR (2DS3) more than the AB1 phenotype. 26 The remaining KIR phenotypes belonging to BB were found at low frequency in both groups.
Linkage disequilibrium
Comparison of linkage disequilibrium values for KIR gene pairs between controls and leukemic patients are illustrated in Table 3 . The significant linkage disequilibrium values observed in the control group are comparable with those of previous population studies and segregated the KIR genes into two haplotypes; haplotype A, comprising 2DL1, 2DL3, 3DL1, 2DS4; haplotype B comprising 2DL2, 2DS1, 2DS2, 2DS3, 2DS5 and 3DS1. 12, 13, 24, 26, 29 This was not seen in the leukemic patient group. Moreover, the strong positive association between KIR3DL1 and KIR2DS4 observed in the controls was only borderline significant (P c ¼ 0.04) in the leukemic patients. In addition, most of the significant negative associations between KIR members of the two haplotypes (2DL1-2DL2/2DS2/2DS3, 2DL3-2DS2/2DS3, 3DL1-2DS1/2DS3/3DS1 and 2DS4-2DS1/ 2DS5/3DS1) occurred in the controls were not apparent in the leukemic patients (Table 3) .
Discussion
NK cells participate in the innate immunity against tumor or virus-infected cells with abnormal expression of HLA class I molecules. It has been reported that leukemic cells can have downregulated expression of HLA class I molecules and in some situations show a complete loss of a HLA class I allele. [17] [18] [19] [20] Apparently, the NK cells of these patients are not able to destroy 
Figure 1
Frequency of major KIR phenotypes in controls and leukemic patients. Differences in the frequency of AA, BB, AB and other KIR phenotypes between controls and leukemic patients were assessed by Yates-corrected P-values (P c ). The P c -values are shown above the bars. The phenotypes that differ from the main KIR phenotypes are grouped together as 'others'.
Natural killer cell receptor phenotypes in leukemia S Verheyden et al these leukemic cells and may allow malignant cells to escape from innate immune control. This failure may be due to the fact that NK cells are part of the malignant clone and therefore might have a decreased function. 31 An alternative hypothesis could be that these patients may display a NKR genotype incapable of destroying leukemic cells with aberrant expression of HLA class I molecules.
In the present study, 13 NKR (11 KIR and two CD94/NKG2) genes were typed by PCR-SSP in 96 leukemic patients and compared with those of 148 healthy controls. The frequency of KIR genes and KIR phenotypes observed in our control population did not differ substantially from the frequency previously reported in other Caucasoid populations 12, 13, 24, 26, 27, 29 (data not shown). The most frequently occurring phenotype in the control population was AA1 (31.1%), which is consistent with other Caucasian populations studied.
12,13,24,26,27,29 However, it was interesting to note that particular KIRs and KIR phenotypes appeared to be more frequent in leukemic patients compared to the healthy controls. We identified a substantial number of leukemic patients (51.0%) with specific KIR phenotypes belonging to the AB phenotype. Heterozygous combinations of group A and B haplotypes generally lead to a higher number of inhibitory and activating KIR genes. Moreover, the AB phenotype is characterized by two genes encoding group 1 HLA-C-specific inhibitory KIRs (2DL2 and 2DL3) and one encoding group 2 HLA-C-specific inhibitory KIR (2DL1). 12, 13 The frequency of the inhibitory KIR2DL2 was significantly higher in the leukemic patients in contrast to the controls and is probably related to the high prevalence of the AB phenotype in this population. We also observed that only one patient lacked the inhibitory KIR3DL1 specific for HLA-Bw4. This frequency was higher in the controls (6.8%) as similarly found in other studies.
12,13,24,27 Table 2 Distribution of specific KIR phenotypes in controls and leukemic patients Phenotype frequency (%) 
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A previous study demonstrated a selective downregulation of HLA-Bw6 associated with HLA-Bw4 preservation on leukemic cells at diagnosis and suggested that this would provide leukemic cells with an escape mechanism from NK cells. 17 However, no information today is available on the expression of HLA-C at the allelic level on leukemic cells nor on the expression of HLA class I of patients at more advanced stages of their disease.
Most interesting was the presence of two specific KIR phenotypes within the AB phenotype: the phenotypes AB1 and AB9 were significantly associated with AML and CML patients, respectively. These KIR phenotypes, containing all inhibitory and a few activating KIR genes, represented together approximately 30% of the profiles found in the leukemic patients studied. Altogether, the above data may imply that the NK cells of a substantial number of leukemic patients are under strong inhibitory conditions caused by the presence of many inhibitory KIRs.
The strong negative association between KIR members of the A and B haplotypes observed in the controls and other Caucasians were not seen in the leukemic patients. 12, 13, 24, 26, 29 This could be due to the relative high frequency of coexistence of both haplotypes A and B in leukemic patients. The very strong positive linkage between 3DL1 and 2DS4 was not so apparent in the leukemic patients. This observation could be related to the very high frequency of KIR3DL1, which was nearly found in all leukemic patients. Finally, we found four patients negative for the activating NKG2C in contrast to one individual in the control group. Other studies as well found a low percentage of individuals negative for NKG2C and suggested that the variation in the NKG2 family is restricted to this activating receptor. 12, 24, 27 In conclusion, our study suggests that susceptibility to leukemia may be influenced at least in part by the NKR phenotype. An important percentage of leukemic patients express a NKR phenotype with major inhibitory capacity in favor of escaping from NK cell control. Along this line, a previous functional study demonstrated that downregulation of natural cytotoxicity receptors (NK p46, NK p30, NK p44) on NK cells in AML patients could be an additional mechanism of tumor escape from NK cell immunity. 32 Further investigation on the polymorphisms of NKR genes, their HLA ligands and the expression of HLA class I molecules on leukemic cells are crucial to understand the underlying mechanism(s) of the possible NK cell dysfunction in leukemia. Natural killer cell receptor phenotypes in leukemia S Verheyden et al
